Search
Research
Influenza disease and vaccination in children in AustraliaOver the past decade, multiple initiatives have been implemented to strengthen influenza vaccination programs in Australia, with an increasing focus on children. In this article, we review these changes, the events that prompted them, and how they have influenced influenza vaccine uptake in Australia.
Research
Developmental outcomes following vaccine-proximate febrile seizures in childrenTo compare the developmental and behavioral outcomes of children experiencing an initial vaccine-proximate (VP) febrile seizure (FS) to those having a non-VP-FS (NVP-FS) and controls who have not had a seizure.
Research
Progress toward a global group a streptococcal vaccineThe desire for an effective vaccine arises from the large burden of disease caused by the bacterium, particularly rheumatic fever and rheumatic heart disease.
Research
Group A streptococcal vaccines: Paving a path for accelerated developmentVaccine prevention of GAS infections and their immunological complications has been a goal of researchers for decades.
News & Events
New Co-directors for the Wesfarmers Centre of Vaccines and Infectious DiseasesDr Lea-Ann Kirkham and Dr Chris Blyth have been appointed as Co-Directors
News & Events
Vaccination Q&A with Dr Chris BlythImmunisation plays an important role in preventing disease within our community. Watch Dr Chris Blyth answer some commonly asked questions about vaccines.
News & Events
An open letter to WA familiesMy colleagues and I at Perth's The Kids Research Institute Australia study how to make current vaccines work better, reduce common side effects, and develop new vaccines.
News & Events
New vaccine may provide broader protection against cervical cancerJust under 150 Perth women have contributed to major international research at the Telethon Institute for Child Health Research.
News & Events
Perth researchers to trial bird flu vaccinePerth researchers have begun a trial to test the effectiveness of a new vaccine to protect against the potentially deadly bird flu.
Research
Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccineWe have previously reported the safety and immunogenicity four weeks after two doses of the Clover COVID-19 vaccine candidate, SCB-2019, a stabilized pre-fusion form of the SARS-CoV-2 S-protein (S-trimer). We now report persistence of antibodies up to 6 months after vaccination, and cross-neutralization titers against three Variants of Concern.